Hvivo

HVO · AIM · Health Care · mcap £41m · 5.8p

hVIVO runs human challenge trials, in which volunteers are deliberately infected with viruses such as flu and RSV in quarantine units to test vaccines and antivirals for pharma and biotech clients. It also offers laboratory services, early-phase clinical units in Germany and bio-storage.

Recent signals

Negative 15 Sep 2026

FY26 guidance cut from high single-digit growth to about £47m, flat year on year

Guidance of high single-digit growth was replaced by flat revenue on deferrals, with an H1 EBITDA loss of £4.5m. 15 Sep 2026 15 Apr 2026

Positive 15 Sep 2026

Orderbook more than doubled to £65m with CRS Berlin acquired on nominal upfront terms

Contracted orderbook rebuilt from £30m, though the improvement has not yet reached revenue or EBITDA. 15 Sep 2026 27 Aug 2026

Mixed 15 Sep 2026

CFO retiring; NED Brendan Buckley sold shares in Apr 2026

Finance leadership changes and a co-founder selling during a weak period. 15 Sep 2026 24 Apr 2026

Positive 8 Sep 2026

Octopus Investments stake rose from 2.97% to 13.97% over two years

Sustained stake building by an institution, while the share price fell from about 28p to about 6p. 8 Sep 2026 8 Jul 2024

Positive 15 Dec 2025

CEO and CFO bought shares in Jun 2025 and Dec 2025 after profit warning

Executives bought on the open market after the May 2025 cancellation warning. 15 Dec 2025 2 Jun 2025

Capital actions

2026-08-27 acquisition · €0.025m upfront – Acquired CRS Berlin; nominal upfront plus revenue-based earnout of about €6m gross over three years 27 Aug 2026
2025-02-27 acquisition · up to £3.2m – Acquired Cryostore; £2.7m cash and up to £0.5m equity consideration 27 Feb 2025
2025-01-29 acquisition · €10.0m – Acquired two German clinical research units from CRS in cash, funded from existing resources 29 Jan 2025

From the company's own announcements · not investment advice

Company filings. Not investment advice.